Total Price: $0.00
Contact Information
Recombinant Human PD-L1/B7-H1/CD274 Protein (ECD, Fc Tag)(Active)
SKU: PKSH030444-100
Recombinant Human PD-L1/B7-H1/CD274 Protein (ECD, Fc Tag)(Active)
| SKU # | PKSH030444 |
| Expression Host | HEK293 Cells |
Description
| Synonyms | B7 homolog 1, B7-H1, B7H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed Cell Death 1 Ligand 1, Programmed death ligand 1 |
| Species | Human |
| Expression Host | HEK293 Cells |
| Sequence | Met 1-Thr 239 |
| Accession | NP_054862.1 |
| Calculated Molecular Weight | 51.7 kDa |
| Tag | C-mFc |
| Bio-activity | Measured by its ability to inhibit anti-CD3 antibody induced IFNγ secretion in human T lymphocytes. The ED50 for this effect is 2-10 μg/mL. |
Properties
| Purity | > 95 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
Background
Programmed death-1 ligand-1 (PD-L1; CD274; B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain; and together with PD-L2; are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells; PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly; it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.